518 related articles for article (PubMed ID: 29425028)
1. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
[TBL] [Abstract][Full Text] [Related]
2. Attachment Site Cysteine Thiol pK
Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
[TBL] [Abstract][Full Text] [Related]
3. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.
Ruddle BT; Fleming R; Wu H; Gao C; Dimasi N
ChemMedChem; 2019 Jun; 14(12):1185-1195. PubMed ID: 30980702
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
[TBL] [Abstract][Full Text] [Related]
7. Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in Plasma.
Wei C; Zhang G; Clark T; Barletta F; Tumey LN; Rago B; Hansel S; Han X
Anal Chem; 2016 May; 88(9):4979-86. PubMed ID: 27075639
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
[TBL] [Abstract][Full Text] [Related]
10. Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly.
Farràs M; Miret J; Camps M; Román R; Martínez Ó; Pujol X; Erb S; Ehkirch A; Cianferani S; Casablancas A; Cairó JJ
MAbs; 2020; 12(1):1702262. PubMed ID: 31876436
[TBL] [Abstract][Full Text] [Related]
11. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
[TBL] [Abstract][Full Text] [Related]
12. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates.
Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C
J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839
[TBL] [Abstract][Full Text] [Related]
13. A Two-Step Immunocapture LC/MS/MS Assay for Plasma Stability and Payload Migration Assessment of Cysteine-Maleimide-Based Antibody Drug Conjugates.
Dong L; Li C; Locuson C; Chen S; Qian MG
Anal Chem; 2018 May; 90(10):5989-5994. PubMed ID: 29688004
[TBL] [Abstract][Full Text] [Related]
14. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
[TBL] [Abstract][Full Text] [Related]
16. Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates.
Sadowsky JD; Pillow TH; Chen J; Fan F; He C; Wang Y; Yan G; Yao H; Xu Z; Martin S; Zhang D; Chu P; Dela Cruz-Chuh J; O'Donohue A; Li G; Del Rosario G; He J; Liu L; Ng C; Su D; Lewis Phillips GD; Kozak KR; Yu SF; Xu K; Leipold D; Wai J
Bioconjug Chem; 2017 Aug; 28(8):2086-2098. PubMed ID: 28636382
[TBL] [Abstract][Full Text] [Related]
17. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
[TBL] [Abstract][Full Text] [Related]
18. Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies.
Dickgiesser S; Kellner R; Kolmar H; Rasche N
Methods Mol Biol; 2019; 2033():1-14. PubMed ID: 31332743
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
20. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
